Stockscreener 앱 받기
6.19
0.00%
0.00
시간 외 거래:
6.42
0.23
+3.72%
전일 마감가:
$6.19
열려 있는:
$6.21
하루 거래량:
82,023
Relative Volume:
0.65
시가총액:
$345.04M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-2.6453
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
+0.98%
1개월 성능:
+26.33%
6개월 성능:
+52.46%
1년 성능:
-5.06%
1일 변동 폭
$6.00
$6.39
1주일 범위
$5.9401
$6.49
52주 변동 폭
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
6.19 | 345.04M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
What analysts say about Foghorn Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Foghorn Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Autocar Professional
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
What drives Foghorn Therapeutics Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
Is Foghorn Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% – What’s Next? - Defense World
Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
SAIL Stock Analysis and ForecastFree Trading Psychology Coaching - Jammu Links News
What analysts say about Leonardo DRS Inc. stockMarket-beating performance - Jammu Links News
What makes Foghorn Therapeutics Inc. stock price move sharplyHigh Potential Safe Trades - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
(FHTX) Trading Report - news.stocktradersdaily.com
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon - simplywall.st
(FHTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
Foghorn Therapeutics Signs New Lease Agreement - TipRanks
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Exchange Traded Concepts LLC Grows Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
When the Price of (FHTX) Talks, People Listen - news.stocktradersdaily.com
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):